Trial Profile

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAR-T cell therapies (Primary) ; I-131-Apamistamab (Primary)
Indications B-cell lymphoma; Blast crisis; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Proof of concept
Acronyms Iomab-ACT

20 Aug 2025 Planned number of patients changed from 6 to 12.
23 Dec 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
23 Dec 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com